CheckMate 920: Nivolumab Plus Ipilimumab for Renal Cell Carcinoma With Brain Metastases
Posted: Friday, July 30, 2021
During the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Hamid Emamekhoo, MD, of the University of Wisconsin School of Medicine and Public Health, Madison, and colleagues presented their results from CheckMate 920—a phase IIIb/IV trial evaluating the efficacy and safety of nivolumab plus ipilimumab in patients with brain metastases related to renal cell carcinoma (Abstract 4515). They revealed that this combination with subsequent nivolumab yielded no new safety signals, with continued antitumor activity demonstrated.
The investigators focused on 28 patients with previously untreated advanced renal cell carcinoma who had asymptomatic brain metastases. Participants were administered 3 mg/kg of nivolumab and 1 mg/kg of ipilimumab every 3 weeks for four doses. This regimen was followed by 480 mg of nivolumab every 4 weeks for up to 2 years, disease progression, or unacceptable toxicity.
The median patient age was 60 years, with most patients (85.7%) being men. The median follow-up was 24.5 months, and the median duration of therapy was 2.1 months for ipilimumab and 3.4 months for nivolumab. Although no participant achieved a complete response, 10 had stable disease, and 8 reached partial response, yielding an objective response rate of 32%. The median time to response was 2.8 months, with a duration of response of 24.0 months; four patients who responded still have not experienced disease progression, but seven experienced intracranial disease progression.
The median progression-free survival was 9.0 months, but the median overall survival has not yet been reached. Although no grade 5 immune-mediated adverse events were observed, grade 3 to 4 events such as diarrhea/colitis (7.1%), diabetes mellitus (3.6%), hepatitis (3.6%), hypophysitis (3.6%), and rash (3.6%) were reported in some patients.
Disclosure: For full disclosures of the study authors, visit coi.asco.org.